Andrew R. MacBride
Research Subjects
Andrew R. MacBride has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Joe W. Gray
Department of Biomedical Engineering, Oregon Health & Science University; Knight Cancer Institute, Oregon Health & Science University
17 shared publications - Kevin G. Phillips
Convergent Genomics Inc, South San Francisco, California
17 shared publications - Mahdi Goudarzi
Convergent Genomics, South San Francisco, California
17 shared publications - Trevor G. Levin
University of British Columbia, Vancouver, Canada
17 shared publications - Vincent T. Bicocca
Veracyte, South San Francisco, USA
17 shared publications - Adam Scott Feldman
Department of Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
16 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.